Casdatifan

Overview

Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α ( HIF-2α ). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT , and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab ( HY-P99109 ). Casdatifan is applicable for the research of ccRCC.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase | Products > Signaling Pathways > VEGFR

Product Information

• Catalog No.: HY-159644
• CAS No.: 2709069-30-5
• Molecular Formula: C21H17F4NO3S
• Molecular Weight: 439.42
• Purity: 96.37%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution
• Availability: In-stock

Source

Original product source